1The AGIS Investigators , 7. The relationship between control of intraocular pressure and visual field deterioration. The advanced glaucoma intervention study (AGIS):Am J Ophthalmol 2000,130-429
2Goldberg I, Relationship between intraocular pressure and preservation of visual fields in glaucoma. Surv Ophthalmol 2003,48-3
3Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL, Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 2002,47-53
4Eisenberg DL, Toris CB, Camras CB, Bimatoprost and Travoprost : a review of recent studies of two new glaucoma drugs. Surv Ophthalmol 2002,47-105
5Toris BC, Gabelt TB, Kauffman LP, Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008,53-107
6Liang Y, Woodward DF, Guzman VM, LI C, Scott DF et all, Identification and pharmacological characterization of the prostaglandin FP and FP receptor variant complexes. Br J Ophthalmol 2008,154-1079
7Soltau BJ, Zimmerman TJ, Changing paradigms in the medical treatment of glaucoma. Surv Ophthalmol 2002,47-2
8Netland PA, Landry T, Sullivan EK, Andrew R, Silver L,Weiner A,Mallick S, Dickerson J, Bergamini MVW, Robertson SM, Davis AA: The Travoprost Study Group: Travoprost compared with latanoprost and timolol, in patients with open-angle glaucoma or ocular hypertension, Am J Ophthalmol 2001,132-472
9Sherwood M, Brandt J :Bimatoprost Study Groups 1 and 2, Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice daily in patients with elevated intraocular pressure. Surv. Ophthalmol 2001,45
10Cohen JS, Gross RL, Cheetmam JK, VanDenburgh AM, Bernstein P, Whitcup SM, Two &ndashyear double &ndashmasked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension.Surv Ophthalmol 2004,49-45
11Parrish RK, Palmerg P, Sheu WP, A Comparison of Latanoprost, Bimatoprost, and Travoprost in Patients with Elevated Intraocular Pressure. A 12-week, Randomized, Masked-evaluator Multicenter study. Am J Ophthalmol 2003,135-688
12Cantor L, Hoop JS, Morgan L, WuDunn D, Catoria Y, The Bimatoprost- Travoprost Study Group, Intraocular pressure&ndashlowering efficacy of bimatoprost 0,003% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol 2006,90-1370
13Alagöz G, Gürel K, Bayer A, Serin D, Çelebi S, Kukner S, A comparative study of bimatoprost and travoprost: effect on intraocular pressure and ocular circulation in newly diagnosed glaucoma patients. Ophthalmologica 2008,222-88
14zdemir N, zcan AA, Bilgiç E, Bimatoprost, Latanoprost, Travoprost&rsquoun Primer Açik Açili Glokom Olgularin da Erken Dönem Yan Etkileri ve Göz Içi Basinci Üzerine Etkinligi. T. Oft. Gaz. 2004,33-376
15Noecker R, Earl ML, Mundorf T, Silverstein SM, Phillips MP, Comparing bimatoprost and travoprost in black Americans . Curr Med Res Opin. 2006,22-2175
16Akyol S, Köz G, Yarangümeli A, Elhan AI, Kural G, Travaprost, Latanoprost ve bimatoprostun göz içi basinci ve görme alani üzerindeki etkilerinin karsilastirilmasi:Ön çalisma. Türkiye Klinikleri Oftalmoloji Dergisi 2006,15-18
17Stewart WC, Kolkler AE, Stewart JA, Leech J, Jackson AL, Conjonctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol 2003,135-314
18Tosti A, Pazzaglia M, Voudouris S, Tosti G, Hypertrichosis of the eyelashes caused by bimatoprost. J Am Acad Dermatol 2004,51-149
19Wand M, Gaudio AR, Cystoid macular edema associated with ocular hypotensive lipids. Am J Ophthalmol. Mar 133(3) 2002
20Stjernschantz JW, Albert DM, Hu DN, Drago F, Wistrand PJ, Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol 2002,47-162
21Wolf R, Matz H, Zalish M, Pollack A, Orion E, Prostaglandin analogs for hair growth: great expectations. Dermatol Online 2003,9
22Johnstone MA, Albert DM, Prostaglandin-induced hair growth. Surv Ophthalmol 2002,47-185